Washington Legal Foundation chief counsel Richard Samp criticizes a Third Circuit Court of Appeals decision in a Lipitor patent settlement case.
A U.S. Chamber report outlines steps, including by FDA, that can be taken to restrict lawsuit advertising that it says can harm public health.
FDA clears a RadiaDyne 510(k) for two new indications for its OARtrac radiation dose monitoring platform.
FDA commissioner Scott Gottlieb outlines the agencys efforts as part of HHS to address the nations opioid crisis.
FDA sends PTC Therapeutics a complete response letter for its NDA for ataluren for treating nonsense mutation dystrophinopathies.
FDA issues Antares Pharma a complete response letter on its NDA for Xyosted (testosterone enanthate) injection for testosterone replacement therapy.
Federal Register notice: FDA determines that HRA Pharmas Ovrette (norgestrel) tablets, 0.075 mg, was not withdrawn from sale for reasons of safety or ...
OriGen Biomedical recalls two lots of its Reinforced Dual Lumen catheter due to a separation risk involving the clear extension tube from the hub conn...